Are we Bypassing the Biomarker Experts?

0

1. NGS has transformed GU cancer treatment.

2. Pathologists must oversee molecular testing.

3. There are significant workflow barriers in GU pathology.

4. Urine-based tests show potential but require validation.

5. Direct marketing to oncologists bypasses pathologists.

6. Collaboration is essential for effective patient care.

7. Test duplication can affect costs and outcomes.